Allgens Medical Technology Co., Ltd. was established in 2004. It is a Sino-foreign joint venture of medical devices focusing on R&D, production and sales of tissue engineering materials, mainly involving new biodegradable materials. The company has been recognized as a high-tech enterprise in Beijing, a national high-tech enterprise, and was selected as an innovation leading enterprise in the Beijing Biomedical Industry Leap-over Development Project (G20 Project). The company has a 10,000-level clean production workshop, and has established a strict quality management system in accordance with the "Medical Device Manufacturing Quality Management Standard (GMP) Implantable Medical Device Implementation Rules" and YY/T 0287 requirements, and has passed the GMP audit certification of CFDA and international quality management system certification, ISO13485 and ISO9001.

Allgens is a national high-tech enterprise dedicated to the R&D, production and sales of high-end implantable medical devices for tissue regeneration and repair. Relying on the patented technology of Tsinghua University and more than ten years of independent research and development accumulation, a series of biomimetic mineralized collagen synthetic bone repair products have been developed, covering four major application categories of orthopedics, stomatology, plastic surgery, and neurosurgery, with more than 50 varieties . The company's products and technologies now have more than 50 Chinese patents and more than 10 overseas patents.

In May 2021, it successfully listed on SSE STAR Market (Stock code:688613). With its excellent R&D capabilities and expanding productivity, ALLGENS has created a miracle of the rapid development of domestic medical device companies in China.

Allgens's biomimetic mineralized collagen bone repair nedma teria material have now obtained three  CFDA Class III medical device registration certificates in the fields of orthopedics, stomatology, and neurosurgery,as well as the US FDA medical device  registration certificates. The product has been used clinically for more than 200,000 cases in China and the United States, and the bone regeneration and repair effect is good.

Enterprise and Product Qualification

Allgens Medical Co., Ltd. has won the title of national specialized and special new "little giant" enterprise, innovation enterprise of Beijing biomedical industry leapfrog development project (G20 project), national high-tech enterprise, Zhongguancun high-tech enterprise, Beijing municipal enterprise science and technology research and development institution, etc;

Allgens's Products won the national key new products, Beijing independent innovation products, Beijing new technology and new products and many other honors and certification.